These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6266576)

  • 1. Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects.
    MacGregor GA; Markandu ND; Bayliss J; Roulston JE; Squires M; Morton JJ
    Br Med J (Clin Res Ed); 1981 Aug; 283(6288):401-3. PubMed ID: 6266576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
    Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
    Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
    Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
    Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension.
    Jackson B; Cubela R; Johnston CI
    J Hypertens; 1984 Aug; 2(4):371-7. PubMed ID: 6099390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.
    Brunner DB; Desponds G; Biollaz J; Keller I; Ferber F; Gavras H; Brunner HR; Schelling JL
    Br J Clin Pharmacol; 1981 May; 11(5):461-7. PubMed ID: 6268131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.
    Biollaz J; Brunner HR; Gavras I; Waeber B; Gavras H
    J Cardiovasc Pharmacol; 1982; 4(6):966-72. PubMed ID: 6185790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".
    Gavras H; Biollaz J; Waeber B; Brunner HR; Gavras I; Davies RO
    Lancet; 1981 Sep; 2(8246):543-7. PubMed ID: 6116000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous angiotensin II as a determinant of sodium-modulated changes in tissue responsiveness to angiotensin II in normal man.
    Shoback DM; Williams GH; Hollenberg NK; Davies RO; Moore TJ; Dluhy RG
    J Clin Endocrinol Metab; 1983 Oct; 57(4):764-70. PubMed ID: 6309884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for a vasodepressor effect of the angiotensin-converting enzyme inhibitor, MK421 (enalapril), independent of blockade of angiotensin II formation.
    Wilkes BM
    J Cardiovasc Pharmacol; 1984; 6(6):1036-42. PubMed ID: 6084759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effects of MK421, a new angiotensin converting enzyme inhibitor, in man.
    Kasai Y; Abe K; Yasujima M; Tajima J; Seino M; Chiba S; Sato K; Goto T; Omata K; Tanno M
    Tohoku J Exp Med; 1983 Dec; 141(4):417-22. PubMed ID: 6322384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.
    McIntyre M; MacFadyen RJ; Meredith PA; Menard J; Brunner HR; Insuasty J; Reid JL
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):994-1000. PubMed ID: 7564347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I.
    Inglessis N; Nussberger J; Hagmann M; Hiesse-Provost O; Insuasty J; Reid J; Ménard J; Brunner HR
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):986-93. PubMed ID: 7564346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.
    Lewis RA; Baker KM; Ayers CR; Weaver BA; Lehman MR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S12-5. PubMed ID: 2580164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fetotoxicity of angiotensin-converting enzyme inhibition in primate pregnancy: a prospective, placebo-controlled study in baboons (Papio hamadryas).
    Harewood WJ; Phippard AF; Duggin GG; Horvath JS; Tiller DJ
    Am J Obstet Gynecol; 1994 Sep; 171(3):633-42. PubMed ID: 8092208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
    Ajayi AA; Hockings N; Reid JL
    Br J Clin Pharmacol; 1986 Apr; 21(4):349-57. PubMed ID: 3011047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of action and short-term hormonal responses to enalapril (MK 421) in normal subjects.
    Given BD; Taylor T; Hollenberg NK; Williams GH
    J Cardiovasc Pharmacol; 1984; 6(3):436-41. PubMed ID: 6202969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs.
    McCaa RE; Gillespie JB
    Fed Proc; 1984 Apr; 43(5):1336-41. PubMed ID: 6323226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why use angiotensin converting enzyme inhibitors to lower blood pressure?
    MacGregor GA; Markandu ND; Smith SJ; Sagnella GA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 4():S92-7. PubMed ID: 2412021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the pathophysiologic profile of blood pressure determinants during short-term enalapril administration.
    de Leeuw PW; Birkenhäger WH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S26-9. PubMed ID: 2422490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives.
    Redgrave J; Rabinowe S; Hollenberg NK; Williams GH
    J Clin Invest; 1985 Apr; 75(4):1285-90. PubMed ID: 2985655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.